HEXAFIL: Non-interventional study for supportive treatment of chemotherapy induced neutopenia with Filgrastim HEXAL®

HEXAFIL: Non-interventional study for supportive treatment of chemotherapy induced neutopenia with Filgrastim HEXAL® - HEXAFIL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000313

Enrollment

1460

Registered

2010-01-18

Start date

2010-01-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy induced neutropenia D70.1

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.) Patients undergoing antineoplastic therapy and who are treated either prophylactically or interventionally with Filgrastim HEXAL® in case of emerging neutropenia. 2.) Male and female patients at least 18 years old (no upper age limit) 3.) Signed informed consent of the patient to the collection and forwarding of pseudonymised data

Exclusion criteria

Exclusion criteria: 1.) Contraindication according Summary of Products Characteristics (SPC) Filgrastim HEXAL® 2.) Furthermore, patients should not be included in the non-interventional study if they fulfill at least one of the following criteria: a.) Patients who have not signed the informed consent form b.) Patients who have been treated with G-CSF in the current line of chemotherapy treatment c) Female patients who are pregnant or breast-feeding d.) Patients undergoing myelosuppressive or myeloablative therapy followed by autologous transplantation of PBBC, and e.) Patients who are diagnosed with myelodysplastic syndrome (MDS) f.) Patients who are diagnosed with chronic myelogenous leukemia (CML) g.) Patients who are diagnosed with secondary AML h.) Patients who are scheduled for myeloablative treatment followed by bone marrow transplantation i). Patients who are diagnosed with severe chronic neutropenia (SCN), congenital neutropenia, or idiopathic or cyclic neutropenia j.) Patients aged < 55 year who are diagnosed with de novo AML with good cytogenetics [t(8;21), t(15;17), and inv(16)] k.) Patients who are diagnosed with HIV l.) Patients who are diagnosed with hereditary fructose intolerance In line with the Amendment No. 1 (approved by CEC on 06/28/2011), active since 08/17/2011: m). Patients who have been treated with filgrastim HEXAL® for the treatment of chemotherapy-induced neutropenia and who already participated in the non-interventional study HEXAFIL

Design outcomes

Secondary

Measure	Time frame
Efficacy of Filgrastim HEXAL® treatment - application period of Filgrastim HEXAL® (measured as number of days applied per chemotherapy cycle); occurrence of febrile neutropenia, leukocyte count observed before the start of chemotherapy cycle (if available) and lowest leukocyte count observed during the chemotherapy cycle (if available); correlation of Filgrastim HEXAL® administration to tumor entitiy and previous therapy regimen; supportive treatment with antibiotics / fungicides ; assessment of self-administration of Filgrastim HEXAL® (s.c.) by the patients, assessment of the needle protection system; overall rating for efficacy and tolerability by the responsible physician. Additional secundary parameters in line with the Amendment No. 1, active since 08/17/2011: Analysis of the ANC (absolute neutrophil count) before and lowest ANC during the observed chemotherapy cycle; intention of supportive antibiotics/antimycotics therapy	—

Measure

Time frame

Efficacy of Filgrastim HEXAL® treatment - application period of Filgrastim HEXAL® (measured as number of days applied per chemotherapy cycle); occurrence of febrile neutropenia, leukocyte count observed before the start of chemotherapy cycle (if available) and lowest leukocyte count observed during the chemotherapy cycle (if available); correlation of Filgrastim HEXAL® administration to tumor entitiy and previous therapy regimen; supportive treatment with antibiotics / fungicides ; assessment of self-administration of Filgrastim HEXAL® (s.c.) by the patients, assessment of the needle protection system; overall rating for efficacy and tolerability by the responsible physician. Additional secundary parameters in line with the Amendment No. 1, active since 08/17/2011: Analysis of the ANC (absolute neutrophil count) before and lowest ANC during the observed chemotherapy cycle; intention of supportive antibiotics/antimycotics therapy

—

Primary

Measure	Time frame
Safety profile of Filgrastim HEXAL®	—

Countries

Germany

Contacts

Public ContactHans Tesch

Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus

069-451080

Outcome results